Please use this identifier to cite or link to this item:
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE|
Utility of sAxl and Lp-PLA2 biomarkers in early detection of cardiac allograft vasculopathy in heart transplantation patients
|Authors:||Mirabet Pérez, S.; García de Frutos, Pablo ; Ordóñez, J.; Brossa, Vicenç; Muñoz Guijoza, C.H.; López, Laura; Sionis, A.; Roig, E.|
|Citation:||European Society of Cardiology Congress (2015)|
|Abstract:||[Purpose] Cardiac allograft vasculopathy (CAV) remains one of the major limitations
in long-term survival in Heart Transplantation patients (TC). Its diagnosis requires
invasive methods and often is done in advanced stages of the disease. The aim
of this work is to study the utility of two biomarkers in the early detection of CAV,
in particular sAxl (protein involved in vascular remodeling) and Lp-PLA2 (marker of
[Methods] We studied 96 TC. We obtained peripheral blood samples to analyze sAxl and Lp-PLA2 levels at the time that the coronary angiography was done for the diagnosis of CAV. Cardiac allograft vasculopathy was classi¿ed according to the recommendations of the ISHLT.
[Results] Study population included 96 patients, aged 48 +/- 15 years old, 77 % male. In 45 patients t he angiographic study did not show CAV (CAV0), in 27 CAV was mild (CAV1), in 5 moderate (CAV2) and in 19 sever (CAV3). We found no signi¿cant differences in Lp-PLA2 levels (p = 0.8) in patients with or without CAV. In contrast, sAxl levels were signi¿cantly higher (64.7 vs 79.3, p = 0.03) in patients with CAV (CAV 1,2,3)compared to patients without CAV (CAV0). In the logistic regression analysis sAxl levels >74 were associated with increased risk of CAV (Odds Ratio = 2.367; 95% 1015-5520; p = 0.04)
[Conclusion] Monitoring the levels of sAxl could be usefull for identifying patients with CAV development. Conversely, Lp-PLA2 levels don¿t seem to be usefull in early detection of CAV. Further studies with larger number of patients may provide more information on the utility of these biomarkers in the early detection of CAV.
|Description:||Trabajo presentado en el European Society of Cardiology (ESC) Congress, celebrado en Londres, Reino Unido, del 29 de agosto al 2 de septiembre de 2015|
|Appears in Collections:||(IIBB) Comunicaciones congresos|